<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Sci</journal-id>
<journal-id journal-id-type="publisher-id">brainsci</journal-id>
<journal-title-group>
<journal-title>Brain Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">2076-3425</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30065201</article-id>
<article-id pub-id-type="pmc">6120041</article-id>
<article-id pub-id-type="doi">10.3390/brainsci8080142</article-id>
<article-id pub-id-type="publisher-id">brainsci-08-00142</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Patient-Derived Stem Cell Models in <italic>SPAST</italic> HSP: Disease Modelling and Drug Discovery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wali</surname>
<given-names>Gautam</given-names>
</name>
<xref ref-type="aff" rid="af1-brainsci-08-00142">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sue</surname>
<given-names>Carolyn M.</given-names>
</name>
<xref ref-type="aff" rid="af1-brainsci-08-00142">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4446-5371</contrib-id>
<name>
<surname>Mackay-Sim</surname>
<given-names>Alan</given-names>
</name>
<xref ref-type="aff" rid="af2-brainsci-08-00142">2</xref>
<xref ref-type="corresp" rid="c1-brainsci-08-00142">*</xref>
</contrib>
</contrib-group>
<aff id="af1-brainsci-08-00142"><label>1</label>Department of Neurogenetics, Kolling Institute of Medical Research, The University of Sydney, Sydney, NSW 2065, Australia; <email>gautam.wali@sydney.edu.au</email> (G.W.); <email>carolyn.sue@sydney.edu.au</email> (C.M.S.)</aff>
<aff id="af2-brainsci-08-00142"><label>2</label>Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia</aff>
<author-notes>
<corresp id="c1-brainsci-08-00142"><label>*</label>Correspondence: <email>a.mackay-sim@griffith.edu.au</email>; Tel.: +61-7-3735-6009</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2018</year>
</pub-date>
<volume>8</volume>
<issue>8</issue>
<elocation-id>142</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 by the authors.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Hereditary spastic paraplegia is an inherited, progressive paralysis of the lower limbs first described by Adolph Strümpell in 1883 with a further detailed description of the disease by Maurice Lorrain in 1888. Today, more than 100 years after the first case of HSP was described, we still do not know how mutations in HSP genes lead to degeneration of the corticospinal motor neurons. This review describes how patient-derived stem cells contribute to understanding the disease mechanism at the cellular level and use this for discovery of potential new therapeutics, focusing on <italic>SPAST</italic> mutations, the most common cause of HSP.</p>
</abstract>
<kwd-group>
<kwd>neurodegeneration</kwd>
<kwd>microtubule</kwd>
<kwd>organelle transport</kwd>
<kwd>peroxisome</kwd>
<kwd>spastic paraplegia</kwd>
<kwd>SPG4</kwd>
<kwd>
<italic>SPAST</italic>
</kwd>
<kwd>spastin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-brainsci-08-00142">
<title>1. Genetics of Hereditary Spastic Paraplegia (HSP)</title>
<p>Hereditary spastic paraplegia (HSP) is a neurological disorder in which the corticospinal motor neurons degenerate [<xref ref-type="bibr" rid="B1-brainsci-08-00142">1</xref>,<xref ref-type="bibr" rid="B2-brainsci-08-00142">2</xref>]. It is one of the most genetically heterogeneous disorders. To date, more than 84 HSP loci have been mapped and 67 HSP genes identified [<xref ref-type="bibr" rid="B3-brainsci-08-00142">3</xref>]. HSP involves all modes of inheritance including autosomal dominant, autosomal recessive, and X-linked recessive patterns [<xref ref-type="bibr" rid="B4-brainsci-08-00142">4</xref>,<xref ref-type="bibr" rid="B5-brainsci-08-00142">5</xref>], however, inheritance is most commonly autosomal dominant [<xref ref-type="bibr" rid="B4-brainsci-08-00142">4</xref>,<xref ref-type="bibr" rid="B5-brainsci-08-00142">5</xref>,<xref ref-type="bibr" rid="B6-brainsci-08-00142">6</xref>]. <italic>SPAST</italic> gene mutation accounts for up to 40% of autosomal-dominant mutations, making it the most commonly mutated gene in this family of disease [<xref ref-type="bibr" rid="B6-brainsci-08-00142">6</xref>,<xref ref-type="bibr" rid="B7-brainsci-08-00142">7</xref>].</p>
<p>Spastin, encoded by <italic>SPAST</italic>, is a protein of the AAA (ATPase associated with diverse cellular activities) protein family [<xref ref-type="bibr" rid="B8-brainsci-08-00142">8</xref>,<xref ref-type="bibr" rid="B9-brainsci-08-00142">9</xref>]. Spastin regulates multiple cellular functions, including microtubule dynamics [<xref ref-type="bibr" rid="B10-brainsci-08-00142">10</xref>], shaping endoplasmic reticulum [<xref ref-type="bibr" rid="B11-brainsci-08-00142">11</xref>], and regulating lipid droplet metabolism [<xref ref-type="bibr" rid="B12-brainsci-08-00142">12</xref>]. Our review focuses on the microtubule dynamics regulation function of spastin. </p>
</sec>
<sec id="sec2-brainsci-08-00142">
<title>2. Radiology of HSP</title>
<p>In recent studies, cerebral white matter alterations in HSP patients were quantified using diffusion tensor imaging (DTI), a widely used magnetic resonance imaging technique. DTI measures the anisotropic flow of water in white matter tracts [<xref ref-type="bibr" rid="B13-brainsci-08-00142">13</xref>]. White matter diffusion patterns can be influenced by factors such as orientation of the axons in the tract, axon damage, or by the degree of myelination. The common DTI indices are: fractional anisotropy, a measure of sensitivity to changes in orientation of axons along the tracts; mean diffusivity, a measure of magnitude of water diffusion and the presence of obstacles to diffusion [<xref ref-type="bibr" rid="B14-brainsci-08-00142">14</xref>,<xref ref-type="bibr" rid="B15-brainsci-08-00142">15</xref>], and radial diffusion, used to differentiate axonal injury from demyelination [<xref ref-type="bibr" rid="B13-brainsci-08-00142">13</xref>]. The most common radiological changes in a variety of HSP gene mutations are alterations in the corticospinal tract (70% of all studies, 71% of <italic>SPAST</italic> studies) and corpus callosum (80% of all studies, 86% of <italic>SPAST</italic> studies) [<xref ref-type="bibr" rid="B16-brainsci-08-00142">16</xref>,<xref ref-type="bibr" rid="B17-brainsci-08-00142">17</xref>,<xref ref-type="bibr" rid="B18-brainsci-08-00142">18</xref>,<xref ref-type="bibr" rid="B19-brainsci-08-00142">19</xref>,<xref ref-type="bibr" rid="B20-brainsci-08-00142">20</xref>,<xref ref-type="bibr" rid="B21-brainsci-08-00142">21</xref>,<xref ref-type="bibr" rid="B22-brainsci-08-00142">22</xref>,<xref ref-type="bibr" rid="B23-brainsci-08-00142">23</xref>,<xref ref-type="bibr" rid="B24-brainsci-08-00142">24</xref>,<xref ref-type="bibr" rid="B25-brainsci-08-00142">25</xref>]. Loss or damage to axons in the corticospinal tract are consistent with the motor symptoms of the disease, although white matter disturbances are not confined to the corticospinal tract and corpus callosum with involvement at the whole brain level, frontal and temporal lobes, cerebellum, and other regions. These observations were made with a variety of DTI techniques, fractional anisotropy being the commonly quantified measure. It is worth noting that the extent of affected regions may be underestimated due to the limits of DTI sensitivity [<xref ref-type="bibr" rid="B26-brainsci-08-00142">26</xref>]. These changes are consistent with widely distributed axonal damage in the white matter of the brain, including the corticospinal tract, which contains the axons of the motor neurons projecting to the lower motor neurons in the distal spinal cord, whose degeneration is responsible for the clinical manifestations of HSP. There is evidence for correlation between radiological findings and disease severity and duration [<xref ref-type="bibr" rid="B16-brainsci-08-00142">16</xref>,<xref ref-type="bibr" rid="B17-brainsci-08-00142">17</xref>,<xref ref-type="bibr" rid="B19-brainsci-08-00142">19</xref>,<xref ref-type="bibr" rid="B24-brainsci-08-00142">24</xref>]. Future clinical investigations could consider examining late-stage <italic>SPAST</italic> HSP patients for evidence of non-motor manifestations that are seen in patients with other HSP mutations [<xref ref-type="bibr" rid="B27-brainsci-08-00142">27</xref>]. The consistency of the MRI findings suggests that low fractional anisotropy in corticospinal tract and corpus callosum may be useful clinical markers and could be potential biomarkers for future clinical trials. A major aim for researchers is to understand the cellular mechanisms leading to degeneration of the corticospinal tract.</p>
</sec>
<sec id="sec3-brainsci-08-00142">
<title>3. Histological Findings in HSP Patients and Animal Models</title>
<p>Post-mortem studies of six HSP patients showed the loss of small and large fibres of the corticospinal tract leading to significant reductions in axon numbers and tract volumes throughout the spinal cord and into the medulla [<xref ref-type="bibr" rid="B28-brainsci-08-00142">28</xref>]. These cases also showed significant losses in axon numbers and volumes in the ascending sensory tracts. At the cellular level, defects in HSP patient cells have been observed mainly in neurons [<xref ref-type="bibr" rid="B29-brainsci-08-00142">29</xref>,<xref ref-type="bibr" rid="B30-brainsci-08-00142">30</xref>,<xref ref-type="bibr" rid="B31-brainsci-08-00142">31</xref>,<xref ref-type="bibr" rid="B32-brainsci-08-00142">32</xref>]. Axonal swellings and abnormal organelle distribution have been the hallmarks of axonal defects in HSP patients and in mouse models.</p>
<sec id="sec3dot1-brainsci-08-00142" sec-type="subjects">
<title>3.1. HSP Patients</title>
<p>Post-mortem analysis of spinal cord sections at the cervical and lumbar level of two <italic>SPAST</italic> HSP patients carrying missense and frameshift mutations had axonal swellings in the descending axons of the corticospinal tract and dorsal column of the spinal cord [<xref ref-type="bibr" rid="B32-brainsci-08-00142">32</xref>]. The axonal swellings were filled with neurofilaments and mitochondria. Immunohistochemistry study of three <italic>SPAST</italic> HSP cases showed altered mitochondrial distribution in the cell body of spinal cord lower and upper motor neurons, with mitochondria being restricted to the periphery of the neuronal soma, in contrast to uniformly distributed mitochondria in control cells [<xref ref-type="bibr" rid="B31-brainsci-08-00142">31</xref>].</p>
</sec>
<sec id="sec3dot2-brainsci-08-00142">
<title>3.2. Mouse Models</title>
<p><italic>SPAST</italic> mouse models do not exhibit the characteristic corticospinal degeneration, but retain the neuronal defects of axonal swellings and altered organelle distribution. In a mouse model with exon 5–7 deletion in <italic>SPAST</italic> (leading to the lack of the AAA domain in spastin), spinal cord sections of 12 and 24 months homozygous mouse at the cervical and lumbar level did not show any obvious degeneration of the corticospinal or dorsal columns [<xref ref-type="bibr" rid="B33-brainsci-08-00142">33</xref>]. Spinal cord sections of the same homozygous mouse model at the cervical and lumbar levels of four months, 12 months, and 24 months old mouse showed axonal swellings. In contrast, heterozygous mouse had few axonal swellings comparable to control mouse. Comparison of axonal swellings between heterozygous and homozygous 12 months mutant mouse showed 11-fold fewer axonal swellings in heterozygous mouse. The axonal swelling defect in the homozygous model increased linearly with the mouse age, consistent with progressive HSP seen clinically although human patients have heterogeneous <italic>SPAST</italic> mutations [<xref ref-type="bibr" rid="B33-brainsci-08-00142">33</xref>].</p>
<p>Homozygous mouse spinal cord sections also showed abnormal accumulation of neurofilaments and cellular organelles in the axonal swellings, including mitochondria and peroxisomes [<xref ref-type="bibr" rid="B33-brainsci-08-00142">33</xref>], as observed in HSP patient spinal cord sections [<xref ref-type="bibr" rid="B32-brainsci-08-00142">32</xref>]. In another mouse model, with splice donor site mutation in Exon 7 of <italic>SPAST</italic>, spinal cord sections of three month old mice with heterozygous and homozygous mutations mouse there were axonal swellings in the white matter [<xref ref-type="bibr" rid="B32-brainsci-08-00142">32</xref>]. The study did not present their data for wild-type/control mouse, making it unclear whether the axonal phenotype was specific to <italic>SPAST</italic> mutant mouse or was present, regardless. Although the two mouse studies agree on the axonal defect of axonal swellings in HSP, there were inconsistencies. In the former model, the swellings were specific to distal regions of the axons [<xref ref-type="bibr" rid="B33-brainsci-08-00142">33</xref>], whereas in the latter model, the swellings occurred randomly along the length of the axonal compartment [<xref ref-type="bibr" rid="B32-brainsci-08-00142">32</xref>].</p>
<p>In summary, although the mouse models show swelling defects in corticospinal axons that are similar to corticospinal tract axons in <italic>SPAST</italic> HSP patients [<xref ref-type="bibr" rid="B32-brainsci-08-00142">32</xref>], there is no evidence for the degeneration of the corticospinal tract [<xref ref-type="bibr" rid="B28-brainsci-08-00142">28</xref>]. This suggests that axonal defects are sufficient for the motor behaviour deficits in the mouse [<xref ref-type="bibr" rid="B33-brainsci-08-00142">33</xref>] without requiring significant die-back of corticospinal axons. This supports the MRI evidence indicating that the loss of corticospinal axons is a later stage phenomenon. This has implications for the success of future therapeutics, which may be most effective when given early in the disease progression.</p>
</sec>
<sec id="sec3dot3-brainsci-08-00142">
<title>3.3. Other Animal Models</title>
<p>Functional studies in Drosophila and zebrafish have shown that spastin function is essential for motor neurons [<xref ref-type="bibr" rid="B8-brainsci-08-00142">8</xref>,<xref ref-type="bibr" rid="B34-brainsci-08-00142">34</xref>,<xref ref-type="bibr" rid="B35-brainsci-08-00142">35</xref>,<xref ref-type="bibr" rid="B36-brainsci-08-00142">36</xref>]. Knockdown of spastin in zebrafish model, severely impaired axon outgrowth of spinal motor neuron axons with defects in neuronal connectivity, and a disrupted network of stabilised microtubules [<xref ref-type="bibr" rid="B35-brainsci-08-00142">35</xref>]. In Drosophila, the loss of spastin caused loss of synaptic area at the neuromuscular junction. At the same synapse, loss of spastin increased the level of acetylated α-tubulin (a marker of stabilised microtubules), whereas increased spastin reduced the level of acetylated α-tubulin [<xref ref-type="bibr" rid="B36-brainsci-08-00142">36</xref>]. In another study of spastin null mutant Drosophila, there was reduced expression of futsch (another marker of stabilised microtubules) in the synaptic boutons at the neuromuscular junction [<xref ref-type="bibr" rid="B8-brainsci-08-00142">8</xref>]. Thus, both studies agree that a loss of spastin in neuromuscular synaptic boutons leads to changes in stabilised microtubules, the direction of the changes contradict: increased [<xref ref-type="bibr" rid="B36-brainsci-08-00142">36</xref>] vs. decreased [<xref ref-type="bibr" rid="B8-brainsci-08-00142">8</xref>]. These Drosophila models do not show any axonal degeneration, axonal swellings, or organelle distribution defects that are seen in HSP patients.</p>
<p>Genetic manipulation in animal models can help in our understanding of the molecular consequences of spastin mutations, but it is still a challenge to understand the disease mechanism in humans. Perhaps this is because animal models, unlike human patients, are genetically homogeneous and there are major species-specific differences at all levels (anatomy, physiology, genetics, behaviour, cell biology). Genetically modified animal models invariably fail to fully replicate human disease deficits and when used for drug development produce, therapeutics that work well in these animal models, work poorly in humans, which is a common problem in neuroscience therapeutic development [<xref ref-type="bibr" rid="B37-brainsci-08-00142">37</xref>,<xref ref-type="bibr" rid="B38-brainsci-08-00142">38</xref>,<xref ref-type="bibr" rid="B39-brainsci-08-00142">39</xref>]. An alternative to animal models in HSP is to use patient-derived brain tissue or cell models that represent the genetic and phenotypic diversity of the patient population. Brain tissue obtained post mortem poses challenges because of the difficulty in obtaining fresh brain tissue at death, the absence of ability to study progression of the disease when the samples are confined to the end stage, and the lack of ability to investigate genetic and molecular pathologies in living cells. Cells from HSP patients are potential disease models that additionally provide early toxicity testing during the drug discovery process. The challenge is to find appropriate, easily accessible cells. Accessible non-neuronal cells like fibroblasts may not show strong patient-control differences for understanding the cellular basis of neurological diseases [<xref ref-type="bibr" rid="B40-brainsci-08-00142">40</xref>]. Patient-derived stem cells are filing this void.</p>
</sec>
</sec>
<sec id="sec4-brainsci-08-00142">
<title>4. Patient-Derived Stem Cell Models in HSP</title>
<sec id="sec4dot1-brainsci-08-00142">
<title>4.1. Induced Pluripotent Stem Cells</title>
<p>Induced pluripotent stem (iPS) cells [<xref ref-type="bibr" rid="B41-brainsci-08-00142">41</xref>] are generated by genetically reprogramming accessible somatic cells, most often skin fibroblast cells. iPS cells can propagate indefinitely in vitro and can give rise to any cell type of the body, including neurons. iPS cells resemble human embryonic stem cells in aspects of proliferation, morphology, gene expression profiles, pluripotency genes, and differentiation ability. Patient-derived iPS cells have been used for disease modelling of numerous neurological disorders, including Parkinson’s disease [<xref ref-type="bibr" rid="B42-brainsci-08-00142">42</xref>], Amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="B43-brainsci-08-00142">43</xref>], Spinal muscular atrophy [<xref ref-type="bibr" rid="B44-brainsci-08-00142">44</xref>], and Alzheimer’s disease [<xref ref-type="bibr" rid="B45-brainsci-08-00142">45</xref>], and they have been used to screen for drugs [<xref ref-type="bibr" rid="B46-brainsci-08-00142">46</xref>]. To study the underlying disease mechanism of the degenerating corticospinal tract in HSP, it would be ideal to generate neurons that make up the corticospinal tract i.e., the cortical motor pyramidal neurons. Relevant published protocols are available for this [<xref ref-type="bibr" rid="B47-brainsci-08-00142">47</xref>]. But, as axonal loss in HSP is not confined to the corticospinal tract upon which diagnosis is dependent, but is more widespread. This includes regions, such as the corpus callosum, internal capsule, external capsule, and others (refer “Pathology of HSP” section), for which specific differentiation protocols are not yet available.</p>
<p>Two studies of neurons generated from <italic>SPAST</italic> HSP patient-derived iPS cells have reported axonal swellings and axonal transport deficits. Glutamatergic neurons from one iPS cell line carrying the heterozygous <italic>SPAST</italic> c.683-iG &gt; T mutation showed increased axonal swellings and altered mitochondria transport with reductions in the percentage of microtubule-dependent mitochondria, reduced retrograde, and unchanged anterograde transport [<xref ref-type="bibr" rid="B29-brainsci-08-00142">29</xref>]. Another study of glutamatergic neurons that were generated from two iPS cell lines carrying the heterozygous <italic>SPAST</italic> mutation c.1684C &gt; T showed alterations in neuron morphology with a reduced number and length of neurites; increased axonal swellings and altered mitochondria transport with reduced retrograde and increased anterograde transport [<xref ref-type="bibr" rid="B29-brainsci-08-00142">29</xref>,<xref ref-type="bibr" rid="B30-brainsci-08-00142">30</xref>]. Although both of these studies showed that <italic>SPAST</italic> iPS-derived neurons can identify HSP disease-associated neuronal deficits, they do not suggest the mechanism of how the observed axonal defects could lead to axonal degeneration in HSP patients. </p>
<p>iPS cells hold great potential use in disease modelling and drug screening of human diseases because they provide an unlimited source of tissue-specific cells, but there are still technical challenges for their widespread use as disease models [<xref ref-type="bibr" rid="B48-brainsci-08-00142">48</xref>]. Development of non-integrating vectors for reprogramming have obviated some of the off-target effects of early methods of iPS genetic reprogramming, but reprogramming methods are still inefficient, laborious, expensive, and time-consuming posing real challenges to application in multiple labs and in multiple patients. As a consequence of the reprogramming process and prolonged cell culture, iPS cells can develop a wide range of variations, including aneuploidy and chromosomal aberrations, single nucleotide variations, and sub-chromosomal copy number variations [<xref ref-type="bibr" rid="B49-brainsci-08-00142">49</xref>,<xref ref-type="bibr" rid="B50-brainsci-08-00142">50</xref>,<xref ref-type="bibr" rid="B51-brainsci-08-00142">51</xref>]. Differentiation of iPS cells into neurons can be problematic: efficiency was low and variable between iPS cell lines that were generated by the same reprogramming method, different reprogramming methods, and between iPS cell lines that are generated from the same parental fibroblast cell line [<xref ref-type="bibr" rid="B52-brainsci-08-00142">52</xref>]. With time and cost limiting the numbers of disease-specific iPS cell studies, such technical issues in reprogramming and neuronal differentiation are potential confounds that need to be resolved when trying to identify subtle disease-specific defects in patient iPS-based cell models. </p>
</sec>
<sec id="sec4dot2-brainsci-08-00142">
<title>4.2. Adult Olfactory Stem Cells</title>
<p>Patient-derived olfactory cells and tissues are increasingly used for investigating neurodegenerative and neuropsychiatric diseases for which they have certain advantages over iPS cell models [<xref ref-type="bibr" rid="B53-brainsci-08-00142">53</xref>]. The olfactory sensory neurons are continually regenerated throughout life from stem cells in the olfactory mucosa, which is the organ of smell in the nose, which is accessible by simple biopsy in most people under local anaesthetic [<xref ref-type="bibr" rid="B54-brainsci-08-00142">54</xref>]. Olfactory neurosphere-derived cells (ONS cells), are adult stem cells that are derived from the olfactory mucosa. These are a multipotent stem cell, able to make neurons and glia as well as many other cell types of the body (heart, liver, kidney, blood: [<xref ref-type="bibr" rid="B55-brainsci-08-00142">55</xref>]). ONS cells can be generated quickly from patient biopsies using standardised protocols [<xref ref-type="bibr" rid="B56-brainsci-08-00142">56</xref>]. They do not proliferate indefinitely but frozen stocks can be created and used for many years as a novel way of investigating brain diseases and for drug discovery using high throughput biology and automated screening to generate and test hypothesis [<xref ref-type="bibr" rid="B38-brainsci-08-00142">38</xref>,<xref ref-type="bibr" rid="B39-brainsci-08-00142">39</xref>]. ONS cells have revealed significant disease-specific phenotypes in schizophrenia, Parkinson’s disease, ataxia telangiectasia, epilepsy, autism, familial dysautonomia, and HSP [<xref ref-type="bibr" rid="B57-brainsci-08-00142">57</xref>,<xref ref-type="bibr" rid="B58-brainsci-08-00142">58</xref>,<xref ref-type="bibr" rid="B59-brainsci-08-00142">59</xref>,<xref ref-type="bibr" rid="B60-brainsci-08-00142">60</xref>,<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>,<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>,<xref ref-type="bibr" rid="B63-brainsci-08-00142">63</xref>,<xref ref-type="bibr" rid="B64-brainsci-08-00142">64</xref>]. Unlike iPS cells, ONS cells are not genetically reprogrammed and they are relatively easy to generate in vitro and cost-effective to generate and maintain [<xref ref-type="bibr" rid="B38-brainsci-08-00142">38</xref>]. Like iPS cells, neuronal differentiation of ONS cells is variable and not efficient [<xref ref-type="bibr" rid="B53-brainsci-08-00142">53</xref>,<xref ref-type="bibr" rid="B55-brainsci-08-00142">55</xref>], and there are no protocols for differentiating them into specific neuronal populations as there are for iPS cells, thus limiting the ability to use ONS-derived cells to investigate defined neurons, such as cortical neurons.</p>
<p>As cell models of HSP, we generated ONS cell lines from nine patients with heterozygous <italic>SPAST</italic> mutations and ten healthy controls. By comparing the differences between patient- and control-derived cells, we identified altered cell functions in patient cells and identified drugs that restored their function, thus making them potential new therapeutics for HSP. In discovery phase, an initial unbiased transcriptomics analysis showed that 57% of all mRNA transcripts were affected in patient cells suggesting that <italic>SPAST</italic> mutations cause major changes in cellular homeostasis [<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>]. Consistent with this hypothesis, gene ontology analysis of the dysregulated transcripts pointed to widespread alterations in the expression of multiple genes that are involved in microtubule formation and dynamics. Proteomic analysis revealed a 50% reduction in spastin in patient cells when compared to controls, indicating the link between gene haploinsufficiency and protein expression in <italic>SPAST</italic> patient cells. Further analysis of microtubule-associated proteins showed a 50% reduction in acetylated α-tubulin, a marker of stable microtubules and substrate of spastin, and a 150% increase in stathmin, a microtubule destabilising enzyme. This reduction in stabilised microtubules when spastin is reduced may be explained by increased expression of stathmin, as a consequence of homeostatic feedback regulation of microtubule dynamics.</p>
<p>Quantitative automated microscopic analysis confirmed the loss of stable microtubules throughout the patient cells and altered the distributions of peroxisomes (more numerous at the periphery of patient cells compared to control cells) and mitochondria (less numerous at the periphery), suggesting that organelle transport was impaired in patient cells [<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>]. Displacement of mitochondria was also seen in neuronal cell bodies in the HSP spinal cord [<xref ref-type="bibr" rid="B31-brainsci-08-00142">31</xref>]. Peroxisome transport was analysed by live-cell imaging of patient and control ONS cells: the average speeds of peroxisome transport was significantly reduced in patient cells [<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>].</p>
<p>Intracellular microtubule-dependent organelle transport is essential in neuronal axons that depend solely on microtubules for intracellular transport to and from their distally located synapses (up to 1 m in cortical neurons) [<xref ref-type="bibr" rid="B65-brainsci-08-00142">65</xref>]. We tested microtubule-dependency of peroxisome transport by differentiating ONS cells into immature neurons with long neurites that mimicked axons, comprising axial microtubules without the background of actin cytoskeleton that is found in cell bodies [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. With this cytoarchitecture, the patient-control differences were amplified in the longer neuron-like cells when compared to smaller ONS cells (~50% reduction in mean speed compared to ~10% in ONS cells) [<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>,<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. Additionally, there was a 25% reduction in the numbers of peroxisomes in patient neurites as compared to control neurites and a relative reduction in the number of peroxisomes transported retrogradely [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. For further evidence of microtubule-dependence, we separately analysed the transport speeds of the fast peroxisomes as they are known to be dependent on microtubules for their transport [<xref ref-type="bibr" rid="B66-brainsci-08-00142">66</xref>]. The speeds of the fast peroxisomes in patient-derived neurites were significantly less than in controls [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. Peroxisome movement is saltatory, with short bursts of movement followed by rest periods. Peroxisome speeds are governed in part by the number and duration of these saltatory movements [<xref ref-type="bibr" rid="B66-brainsci-08-00142">66</xref>]. This was investigated by quantifying time-dependent movements of the fast peroxisomes. As there was no patient-control difference in number and duration of salutatory events in the microtubule-dependent fast peroxisomes, the speed reduction of the peroxisome population in patient cells is likely due to the reduced availability of stabilised microtubules in patient cells, rather than reduced ability of peroxisomes to attach and move along stabilised microtubules as a consequence of mutated spastin in patient cells [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. This hypothesis was confirmed when stabilised microtubule content was raised pharmacologically to control levels, which restored peroxisome transport speeds to control levels [<xref ref-type="bibr" rid="B58-brainsci-08-00142">58</xref>].</p>
<p>Peroxisomes are important regulators of oxidative state in cells, especially the metabolism of hydrogen peroxide [<xref ref-type="bibr" rid="B67-brainsci-08-00142">67</xref>]. So, deficits in peroxisome transport could reduce cell viability due to oxidative stress. This was confirmed in <italic>SPAST</italic> patient ONS cells that are under oxidative stress when compared to control cells, and more sensitive to hydrogen peroxide [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. In patient cells, there was a significant increase in the expression of 4HNE, a lipid peroxidation product, under baseline culture conditions and after exposure to hydrogen peroxide. Additionally, exposure to hydrogen peroxide was more toxic to patient cells when compared to control cells, as assessed by ATP production and cell viability assays. This is the first evidence of oxidative stress in <italic>SPAST</italic> HSP patient-derived cells and it links <italic>SPAST</italic> mutations with the induction of cell death via a reduction in stabilised microtubules. This mechanism was confirmed in patient cells when acetylated α-tubulin levels were restored pharmacologically to control levels and their oxidative response to hydrogen peroxide was also restored [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>].</p>
<p>Peroxisomes and mitochondria interact to regulate responses to oxidative stress and altered biogenesis, dynamics, or metabolism in one organelle can affect the other [<xref ref-type="bibr" rid="B68-brainsci-08-00142">68</xref>]. Mitochondria contribute fundamentally to cellular homeostasis, including ATP production and dynamics, metabolism of reactive oxygen species, and calcium and lipid homeostasis. The major functions of peroxisomes include fatty acid α- and β-oxidation, ether lipid (esp. plasmalogen) biosynthesis, and reactive oxygen species homeostasis [<xref ref-type="bibr" rid="B67-brainsci-08-00142">67</xref>]. Therefore, in <italic>SPAST</italic> HSP, dysfunctions in microtubule-dependent transport of peroxisomes and mitochondria could have profound consequences for many cell functions, requiring dynamic homeostatic feedback. This may help to explain the need for the genome-scale changes that were observed in the transcriptome of <italic>SPAST</italic> patient cells [<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>]. Presumably, <italic>SPAST</italic> mutations would affect organelle transport in all cells of the body, but with more profound effects in long axons that depend on microtubules alone for organelle transport. In agreement with this, is evidence that <italic>SPAST</italic> patient muscle is morphologically normal, despite similarly large magnitude changes in the transcriptome and disruption of microtubule pathways [<xref ref-type="bibr" rid="B69-brainsci-08-00142">69</xref>].</p>
<p>Peroxisome and mitochondria gene mutations are associated with numerous developmental and other deficits in several neurological diseases [<xref ref-type="bibr" rid="B70-brainsci-08-00142">70</xref>,<xref ref-type="bibr" rid="B71-brainsci-08-00142">71</xref>,<xref ref-type="bibr" rid="B72-brainsci-08-00142">72</xref>,<xref ref-type="bibr" rid="B73-brainsci-08-00142">73</xref>], including HSP [<xref ref-type="bibr" rid="B74-brainsci-08-00142">74</xref>], and impaired mitochondrial and peroxisomal regulation of oxidative stress have been implicated in the aetiology of chronic conditions, such as inflammation, type 2 diabetes, neurodegeneration, and aging [<xref ref-type="bibr" rid="B75-brainsci-08-00142">75</xref>]. <italic>SPG7</italic> HSP patient-derived fibroblasts are more sensitive to hydrogen-peroxide with lower ATP production and viability when compared to control fibroblasts [<xref ref-type="bibr" rid="B76-brainsci-08-00142">76</xref>].</p>
<p>Neurons are particularly vulnerable to oxidative stress, related to the unique functional and structural organisation of neurons. Neurons have a very high requirement for oxygen for intracellular ion homoeostasis, which is essential for propagation of action potentials [<xref ref-type="bibr" rid="B77-brainsci-08-00142">77</xref>,<xref ref-type="bibr" rid="B78-brainsci-08-00142">78</xref>]. Neurons are enriched in polyunsaturated fatty acids that are primary targets of reactive oxygen species-induced oxidative damage [<xref ref-type="bibr" rid="B78-brainsci-08-00142">78</xref>]. Oxidative stress leading to an increase in 4HNE can also damage the blood brain barrier by increasing its permeability [<xref ref-type="bibr" rid="B79-brainsci-08-00142">79</xref>]. These features may explain why the long corticospinal neurons are more susceptible to compromised organelle transport in HSP, with injury starting distally in these long axons with progressive axon die-back along the corticospinal tract. This hypothesis fits well with the progressive clinical presentation of <italic>SPAST</italic> HSP patients whose initially moderate symptoms increase in severity over time as initial axon impairment leads increasingly to axon death and die-back.</p>
</sec>
<sec id="sec4dot3-brainsci-08-00142">
<title>4.3. Two Stem Cell Models Combined</title>
<p>Patient and control-derived ONS cells are relatively easy to generate and freeze/thaw in vitro, making them suitable for multiple high-through put assays for hypothesis generation and the discovery of disease-associated cell dysfunctions. ONS cells are neural progenitors but they are not neurons and so may not reveal neuron-specific dysfunctions resulting from disease-associated mutations. Our disease-modelling approach is to use patient- and control-derived ONS cells as discovery tools to generate hypothesis and to understand the domain of deficits that are associated with HSP mutations and to use this understanding to screen for possible therapeutic drug candidates. Specific hypotheses are then validated in neurons differentiated from patient-derived iPS cells, keeping those experiments to a minimum because they are more time-consuming to generate and expensive to maintain than ONS cells. We see this two-stage approach as the fastest and most inexpensive way to use patient-derived stem cells for drug discovery and clinical outcomes. We generated 11 iPS cell lines from three <italic>SPAST</italic> patients and three healthy controls and differentiated them into cortical neurons (unpublished data) [<xref ref-type="bibr" rid="B80-brainsci-08-00142">80</xref>]. Like ONS cells, <italic>SPAST</italic> patient-derived neurons had reduced spastin, reduced acetylated α-tubulin, reduced transport of peroxisomes, and were more vulnerable to hydrogen peroxide-induced oxidative stress demonstrated by increased axonal degeneration (unpublished data) [<xref ref-type="bibr" rid="B80-brainsci-08-00142">80</xref>].</p>
</sec>
<sec id="sec4dot4-brainsci-08-00142">
<title>4.4. Tubulin-Binding Drugs as Therapeutic Candidates</title>
<p><italic>SPAST</italic> patient-derived ONS cells and patient-derived neurons demonstrate reduced levels of stabilised microtubules, impaired peroxisome transport, increased oxidative stress, and sensitivity to hydrogen peroxide, leading to reduced cell viability and increased axon degeneration (<xref ref-type="fig" rid="brainsci-08-00142-f001">Figure 1</xref>). To correct these deficits, we reasoned that it may not be necessary to correct the spastin insufficiency directly but it may only be required to correct the downstream homeostatic change in acetylated α-tubulin. Microtubule-dependent organelles are transported along microtubules of polymerised tubulin [<xref ref-type="bibr" rid="B81-brainsci-08-00142">81</xref>]. Tubulin normally undergoes various post-translational modifications [<xref ref-type="bibr" rid="B82-brainsci-08-00142">82</xref>], including acetylation of α-tubulin, which is considered to be a signal for the motor proteins to tether for organelle transport [<xref ref-type="bibr" rid="B81-brainsci-08-00142">81</xref>,<xref ref-type="bibr" rid="B82-brainsci-08-00142">82</xref>,<xref ref-type="bibr" rid="B83-brainsci-08-00142">83</xref>]. When considering this, restoring levels of acetylated α-tubulin in patient-derived cells would increase the tethering of peroxisomes and increase the numbers of microtubule transported peroxisomes and increase the average transport speeds of the peroxisome population. With this logic, we investigated tubulin-binding drugs for their effects on peroxisome transport in patient-derived ONS cells and neurons given their ability to disrupt microtubule dynamics in other cells: taxol and epothilones promote the assembly of microtubules [<xref ref-type="bibr" rid="B84-brainsci-08-00142">84</xref>,<xref ref-type="bibr" rid="B85-brainsci-08-00142">85</xref>], vinblastine inhibits assembly of microtubules [<xref ref-type="bibr" rid="B86-brainsci-08-00142">86</xref>] and noscapine alters the steady state dynamics of microtubule assembly [<xref ref-type="bibr" rid="B87-brainsci-08-00142">87</xref>]. Vinblastine reduced the number of axonal swellings in <italic>SPAST</italic> patient iPS cell-derived neurons [<xref ref-type="bibr" rid="B29-brainsci-08-00142">29</xref>]. Taxol and vinblastine also reduced axonal swellings in a <italic>SPAST</italic> mouse model [<xref ref-type="bibr" rid="B88-brainsci-08-00142">88</xref>]. </p>
<p>Using automated high content imaging, we first identified low concentrations of four tubulin-binding drugs (taxol, vinblastine, epothilone D, and noscapine) that increased the levels of acetylated α-tubulin in patient ONS cells to levels in control ONS cells [<xref ref-type="bibr" rid="B58-brainsci-08-00142">58</xref>]. We then quantified the effects of these low doses of tubulin-binding drugs on peroxisome transport, demonstrating that they restored peroxisome transport in patient cells to control cell speeds by increasing the number of fast microtubule-dependent peroxisomes [<xref ref-type="bibr" rid="B58-brainsci-08-00142">58</xref>,<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. Epothilone D also reduced the sensitivity to hydrogen peroxide-induced oxidative stress [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]. Similar results were observed in neurons that were generated from patient-derived iPS cells: epothilone D and noscapine also rescued peroxisome axon transport deficits and ameliorated axonal degeneration induced by hydrogen peroxide (unpublished) [<xref ref-type="bibr" rid="B80-brainsci-08-00142">80</xref>]. These results confirm that impaired peroxisome transport in patient cells is a consequence of reduced levels of acetylated α-tubulin in patient cells, and this was evident in patients with a variety of different mutations in <italic>SPAST</italic>. They also identify tubulin-binding drugs as potential therapies for HSP (<xref ref-type="table" rid="brainsci-08-00142-t001">Table 1</xref>). Epothilone D and noscapine are permeant to the blood brain barrier, and are hence potentially able to reach the cortical motor neurons and their axons in patients.</p>
<p>Deficits in microtubule-associated proteins and impaired organelle transport are emerging as common mechanisms in several motor neuron diseases and neurodegenerative disorders [<xref ref-type="bibr" rid="B89-brainsci-08-00142">89</xref>,<xref ref-type="bibr" rid="B90-brainsci-08-00142">90</xref>,<xref ref-type="bibr" rid="B91-brainsci-08-00142">91</xref>], while chronic oxidative stress is seen as another mechanism for neuronal loss in neurodegenerative diseases [<xref ref-type="bibr" rid="B92-brainsci-08-00142">92</xref>,<xref ref-type="bibr" rid="B93-brainsci-08-00142">93</xref>]. Our evidence in patient-derived cells demonstrates a direct link between these mechanisms for peroxisome transport in HSP patients with a variety of <italic>SPAST</italic> mutations. This mechanism may also apply to mitochondria whose transport is impaired in other <italic>SPAST</italic> patient-derived cells [<xref ref-type="bibr" rid="B29-brainsci-08-00142">29</xref>,<xref ref-type="bibr" rid="B30-brainsci-08-00142">30</xref>].</p>
<p>The tubulin-binding drugs that we used in our studies have been “re-purposed” from cancer therapies and large doses have passed phase I clinical trials, demonstrating their safety. The drug doses in this study are much lower than used clinically [<xref ref-type="bibr" rid="B94-brainsci-08-00142">94</xref>] and did not show any cytotoxicity to patient-derived cells [<xref ref-type="bibr" rid="B58-brainsci-08-00142">58</xref>]. In progressing to clinical trial, epothilone D and noscapine are attractive candidates as they can readily cross the blood brain barrier and [<xref ref-type="bibr" rid="B95-brainsci-08-00142">95</xref>,<xref ref-type="bibr" rid="B96-brainsci-08-00142">96</xref>] in contrast to the taxol and vinblastine [<xref ref-type="bibr" rid="B97-brainsci-08-00142">97</xref>]. This “repurposing” of approved drugs can be important for rare neurological disorders, like HSP, as it reduces the time and costs involved in developing a new drug, making it unprofitable for pharmaceutical companies. </p>
</sec>
</sec>
<sec id="sec5-brainsci-08-00142">
<title>5. Conclusions</title>
<p>With the many genes that can cause HSP, there is a real challenge in understanding the genetic and cellular mechanisms of disease and in devising individual therapies. It is not obvious from the causative mutated genes if there are any common cellular mechanisms that can be targeted for therapy. These might be revealed by the use of patient-derived stem cells, as outlined here for <italic>SPAST</italic> HSP. As discussed, it is expensive in time and money to generate iPS cells and this may be limiting for research on rare diseases like HSP. The strategy illustrated here, using two patient-derived stem cell models, olfactory neural stem cells and induced pluripotent stem cells, provides an efficient system to understand the disease mechanism at a cellular level and to develop therapeutics with the cheaper and easier ONS cells that are used for hypothesis generation and testing and iPS cell-derived neurons used for validation. With <italic>SPAST</italic> HSP, the most common form, as a starting point; the way is now open to emulate this research strategy for other forms. As knowledge builds for the effects of different mutations on cell phenotype, common and discrete disease mechanisms will be revealed and appropriate therapeutics can be devised.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We are very grateful to the participants and funders of our studies.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, G.W. and A.M.-S.; Writing-Original Draft Preparation, G.W.; Writing-Review &amp; Editing, G.W., C.M.S. and A.M.-S.; Funding Acquisition, C.M.S. and A.M.-S.</p>
</notes>
<notes>
<title>Funding</title>
<p>Our research work was supported by grants from the Hereditary Spastic Paraplegia Research Foundation Incorporated, the Spastic Paraplegia Foundation Incorporated and the National Health &amp; Medical Research Council, Australia.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-brainsci-08-00142">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salinas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Proukakis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Hereditary spastic paraplegia: Clinical features and pathogenetic mechanisms</article-title>
<source/>Lancet Neurol.
          <year>2008</year>
<volume>7</volume>
<fpage>1127</fpage>
<lpage>1138</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(08)70258-8</pub-id>
<pub-id pub-id-type="pmid">19007737</pub-id>
</element-citation>
</ref>
<ref id="B2-brainsci-08-00142">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedera</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eldevik</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Maly</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rainier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Spinal cord magnetic resonance imaging in autosomal dominant hereditary spastic paraplegia</article-title>
<source/>Neuroradiology
          <year>2005</year>
<volume>47</volume>
<fpage>730</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="doi">10.1007/s00234-005-1415-3</pub-id>
<pub-id pub-id-type="pmid">16143870</pub-id>
</element-citation>
</ref>
<ref id="B3-brainsci-08-00142">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Koht</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stevanin</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Delving into the complexity of hereditary spastic paraplegias: How unexpected phenotypes and inheritance modes are revolutionizing their nosology</article-title>
<source/>Hum. Genet.
          <year>2015</year>
<volume>134</volume>
<fpage>511</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-015-1536-7</pub-id>
<pub-id pub-id-type="pmid">25758904</pub-id>
</element-citation>
</ref>
<ref id="B4-brainsci-08-00142">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Classification of the hereditary ataxias and paraplegias</article-title>
<source/>Lancet
          <year>1983</year>
<volume>321</volume>
<fpage>1151</fpage>
<lpage>1155</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(83)92879-9</pub-id>
</element-citation>
</ref>
<ref id="B5-brainsci-08-00142">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>The hereditary spastic paraplegias: Nine genes and counting</article-title>
<source/>Arch. Neurol.
          <year>2003</year>
<volume>60</volume>
<fpage>1045</fpage>
<lpage>1049</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.60.8.1045</pub-id>
<pub-id pub-id-type="pmid">12925358</pub-id>
</element-citation>
</ref>
<ref id="B6-brainsci-08-00142">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vandebona</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Spast mutations in Australian patients with hereditary spastic paraplegia</article-title>
<source/>Internal Med. J.
          <year>2012</year>
<volume>42</volume>
<fpage>1342</fpage>
<lpage>1347</lpage>
<pub-id pub-id-type="doi">10.1111/j.1445-5994.2012.02941.x</pub-id>
<pub-id pub-id-type="pmid">23252998</pub-id>
</element-citation>
</ref>
<ref id="B7-brainsci-08-00142">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Melo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Coutinho</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The global epidemiology of hereditary ataxia and spastic paraplegia: A systematic review of prevalence studies</article-title>
<source/>Neuroepidemiology
          <year>2014</year>
<volume>42</volume>
<fpage>174</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1159/000358801</pub-id>
<pub-id pub-id-type="pmid">24603320</pub-id>
</element-citation>
</ref>
<ref id="B8-brainsci-08-00142">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherwood</surname>
<given-names>N.T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zinn</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Drosophila spastin regulates synaptic microtubule networks and is required for normal motor function</article-title>
<source/>PLoS Biol.
          <year>2004</year>
<volume>2</volume>
<elocation-id>e429</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pbio.0020429</pub-id>
<pub-id pub-id-type="pmid">15562320</pub-id>
</element-citation>
</ref>
<ref id="B9-brainsci-08-00142">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fröhlich</surname>
<given-names>K.-U.</given-names>
</name>
</person-group>
<article-title>An AAA family tree</article-title>
<source/>J. Cell Sci.
          <year>2001</year>
<volume>114</volume>
<fpage>1601</fpage>
<lpage>1602</lpage>
<pub-id pub-id-type="pmid">11309190</pub-id>
</element-citation>
</ref>
<ref id="B10-brainsci-08-00142">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Errico</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ballabio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rugarli</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics</article-title>
<source/>Hum. Mol. Genet.
          <year>2002</year>
<volume>11</volume>
<fpage>153</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.2.153</pub-id>
<pub-id pub-id-type="pmid">11809724</pub-id>
</element-citation>
</ref>
<ref id="B11-brainsci-08-00142">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>P.-P.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Blackstone</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network</article-title>
<source/>J. Clin. Investig.
          <year>2010</year>
<volume>120</volume>
<fpage>1097</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="doi">10.1172/JCI40979</pub-id>
<pub-id pub-id-type="pmid">20200447</pub-id>
</element-citation>
</ref>
<ref id="B12-brainsci-08-00142">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadopoulos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Orso</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mancuso</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Herholz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gumeni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tadepalle</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jüngst</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tzschichholz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schauss</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Höning</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Spastin binds to lipid droplets and affects lipid metabolism</article-title>
<source/>PLoS Genet.
          <year>2015</year>
<volume>11</volume>
<elocation-id>e1005149</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1005149</pub-id>
<pub-id pub-id-type="pmid">25875445</pub-id>
</element-citation>
</ref>
<ref id="B13-brainsci-08-00142">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basser</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Pierpaoli</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI</article-title>
<source/>J. Magn. Reson.
          <year>2011</year>
<volume>213</volume>
<fpage>560</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmr.2011.09.022</pub-id>
<pub-id pub-id-type="pmid">22152371</pub-id>
</element-citation>
</ref>
<ref id="B14-brainsci-08-00142">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Bihan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mangin</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Poupon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>CA.</given-names>
</name>
<name>
<surname>Pappata</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Molko</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chabriat</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Diffusion tensor imaging: Concepts and applications</article-title>
<source/>J. Magn. Reson. Imaging
          <year>2001</year>
<volume>13</volume>
<fpage>534</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="doi">10.1002/jmri.1076</pub-id>
<pub-id pub-id-type="pmid">11276097</pub-id>
</element-citation>
</ref>
<ref id="B15-brainsci-08-00142">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christian</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The basis of anisotropic water diffusion in the nervous system—A technical review</article-title>
<source/>NMR Biomed.
          <year>2002</year>
<volume>15</volume>
<fpage>435</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">12489094</pub-id>
</element-citation>
</ref>
<ref id="B16-brainsci-08-00142">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezende</surname>
<given-names>T.J.R.</given-names>
</name>
<name>
<surname>de Albuquerque</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lamas</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.R.M.</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Casseb</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Branco</surname>
<given-names>L.M.T.</given-names>
</name>
<name>
<surname>D’Abreu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lopes-Cendes</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multimodal MRI-based study in patients with spg4 mutations</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0117666</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0117666</pub-id>
<pub-id pub-id-type="pmid">25658484</pub-id>
</element-citation>
</ref>
<ref id="B17-brainsci-08-00142">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agosta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scarlato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Spinelli</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Canu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bassi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Casali</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sessa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Copetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hereditary spastic paraplegia: Beyond clinical phenotypes toward a unified pattern of central nervous system damage</article-title>
<source/>Radiology
          <year>2015</year>
<volume>276</volume>
<fpage>207</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1148/radiol.14141715</pub-id>
<pub-id pub-id-type="pmid">25611737</pub-id>
</element-citation>
</ref>
<ref id="B18-brainsci-08-00142">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aghakhanyan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Martinuzzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frijia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vavla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hlavata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baratto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Paparella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Montanaro</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Brain white matter involvement in hereditary spastic paraplegias: Analysis with multiple diffusion tensor indices</article-title>
<source/>Am. J. Neuroradiol.
          <year>2014</year>
<volume>35</volume>
<fpage>1533</fpage>
<lpage>1538</lpage>
<pub-id pub-id-type="doi">10.3174/ajnr.A3897</pub-id>
<pub-id pub-id-type="pmid">24788132</pub-id>
</element-citation>
</ref>
<ref id="B19-brainsci-08-00142">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindig</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>T.-K.</given-names>
</name>
<name>
<surname>Mang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schweikardt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Klose</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Karle</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Schüle</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schöls</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rattay</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>Gray and white matter alterations in hereditary spastic paraplegia type spg4 and clinical correlations</article-title>
<source/>J. Neurol.
          <year>2015</year>
<volume>262</volume>
<fpage>1961</fpage>
<lpage>1971</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-015-7791-7</pub-id>
<pub-id pub-id-type="pmid">26050637</pub-id>
</element-citation>
</ref>
<ref id="B20-brainsci-08-00142">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oğuz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sanverdi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Has</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Temuçin</surname>
<given-names>Ç.</given-names>
</name>
<name>
<surname>Türk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Doerschner</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Tract-based spatial statistics of diffusion tensor imaging in hereditary spastic paraplegia with thin corpus callosum reveals widespread white matter changes</article-title>
<source/>Diagn. Interv. Radiol.
          <year>2013</year>
<volume>19</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">23302284</pub-id>
</element-citation>
</ref>
<ref id="B21-brainsci-08-00142">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garaci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Toschi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lanzafame</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meschini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Simonetti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Santorelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guerrisi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Floris</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Diffusion tensor imaging in SPG11- and SPG4-linked hereditary spastic paraplegia</article-title>
<source/>Int. J. Neurosci.
          <year>2013</year>
<volume>124</volume>
<fpage>261</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.3109/00207454.2013.836705</pub-id>
<pub-id pub-id-type="pmid">23968121</pub-id>
</element-citation>
</ref>
<ref id="B22-brainsci-08-00142">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unrath</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Riecker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ludolph</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Sperfeld</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Kassubek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Whole brain-based analysis of regional white matter tract alterations in rare motor neuron diseases by diffusion tensor imaging</article-title>
<source/>Hum. Brain Mapp.
          <year>2010</year>
<volume>31</volume>
<fpage>1727</fpage>
<lpage>1740</lpage>
<pub-id pub-id-type="doi">10.1002/hbm.20971</pub-id>
<pub-id pub-id-type="pmid">20336652</pub-id>
</element-citation>
</ref>
<ref id="B23-brainsci-08-00142">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warnecke</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Duning</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Schwan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Epplen</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>A novel form of autosomal recessive hereditary spastic paraplegia caused by a new SPG7 mutation</article-title>
<source/>Neurology
          <year>2007</year>
<volume>69</volume>
<fpage>368</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000266667.91074.fe</pub-id>
<pub-id pub-id-type="pmid">17646629</pub-id>
</element-citation>
</ref>
<ref id="B24-brainsci-08-00142">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duning</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Warnecke</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Schirmacher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schiffbauer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Deppe</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Specific pattern of early white-matter changes in pure hereditary spastic paraplegia</article-title>
<source/>Mov. Disord.
          <year>2010</year>
<volume>25</volume>
<fpage>1986</fpage>
<lpage>1992</lpage>
<pub-id pub-id-type="doi">10.1002/mds.23211</pub-id>
<pub-id pub-id-type="pmid">20669295</pub-id>
</element-citation>
</ref>
<ref id="B25-brainsci-08-00142">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>França</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>F.R.S.</given-names>
</name>
<name>
<surname>D’Abreu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lopes-Ramos</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Cendes</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lopes-Cendes</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>White and grey matter abnormalities in patients with SPG11 mutations</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2012</year>
<volume>83</volume>
<fpage>828</fpage>
<lpage>833</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2011-300129</pub-id>
<pub-id pub-id-type="pmid">22696581</pub-id>
</element-citation>
</ref>
<ref id="B26-brainsci-08-00142">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assaf</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pasternak</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Diffusion tensor imaging (DTI)-based white matter mapping in brain research: A review</article-title>
<source/>J. Mol. Neurosci.
          <year>2008</year>
<volume>34</volume>
<fpage>51</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-007-0029-0</pub-id>
<pub-id pub-id-type="pmid">18157658</pub-id>
</element-citation>
</ref>
<ref id="B27-brainsci-08-00142">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Hereditary spastic paraplegia: Clinico-pathologic features and emerging molecular mechanisms</article-title>
<source/>Acta Neuropathol.
          <year>2013</year>
<volume>126</volume>
<fpage>307</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-013-1115-8</pub-id>
<pub-id pub-id-type="pmid">23897027</pub-id>
</element-citation>
</ref>
<ref id="B28-brainsci-08-00142">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deluca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ebers</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The extent of axonal loss in the long tracts in hereditary spastic paraplegia</article-title>
<source/>Neuropathol. Appl. Neurobiol.
          <year>2004</year>
<volume>30</volume>
<fpage>576</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2990.2004.00587.x</pub-id>
<pub-id pub-id-type="pmid">15540998</pub-id>
</element-citation>
</ref>
<ref id="B29-brainsci-08-00142">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denton</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Grenier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rodionov</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Blackstone</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.-J.</given-names>
</name>
</person-group>
<article-title>Loss of spastin function results in disease-specific axonal defects in human pluripotent stem cell-based models of hereditary spastic paraplegia</article-title>
<source/>Stem Cells
          <year>2014</year>
<volume>32</volume>
<fpage>414</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1002/stem.1569</pub-id>
<pub-id pub-id-type="pmid">24123785</pub-id>
</element-citation>
</ref>
<ref id="B30-brainsci-08-00142">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Havlicek</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kohl</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Prots</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Eberhardt</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Denguir</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wend</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Plötz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marchetto</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients’ neurons</article-title>
<source/>Hum. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>2527</fpage>
<lpage>2541</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt644</pub-id>
<pub-id pub-id-type="pmid">24381312</pub-id>
</element-citation>
</ref>
<ref id="B31-brainsci-08-00142">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDermott</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Grierson</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Bingley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wharton</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>K.M.D.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Hereditary spastic paraparesis: Disrupted intracellular transport associated with spastin mutation</article-title>
<source/>Ann. Neurol.
          <year>2003</year>
<volume>54</volume>
<fpage>748</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="doi">10.1002/ana.10757</pub-id>
<pub-id pub-id-type="pmid">14681884</pub-id>
</element-citation>
</ref>
<ref id="B32-brainsci-08-00142">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Vos</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wharton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Manser</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bingley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Milner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients</article-title>
<source/>J. Neurochem.
          <year>2009</year>
<volume>110</volume>
<fpage>34</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06104.x</pub-id>
<pub-id pub-id-type="pmid">19453301</pub-id>
</element-citation>
</ref>
<ref id="B33-brainsci-08-00142">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarrade</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fassier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Courageot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Charvin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vitte</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peris</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Thorel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mouisel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fonknechten</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Roblot</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition</article-title>
<source/>Hum. Mol. Genet.
          <year>2006</year>
<volume>15</volume>
<fpage>3544</fpage>
<lpage>3558</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddl431</pub-id>
<pub-id pub-id-type="pmid">17101632</pub-id>
</element-citation>
</ref>
<ref id="B34-brainsci-08-00142">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orso</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Martinuzzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rossetto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sartori</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Feany</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Daga</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Disease-related phenotypes in a drosophila model of hereditary spastic paraplegia are ameliorated by treatment with vinblastine</article-title>
<source/>J. Clin. Investig.
          <year>2005</year>
<volume>115</volume>
<fpage>3026</fpage>
<lpage>3034</lpage>
<pub-id pub-id-type="doi">10.1172/JCI24694</pub-id>
<pub-id pub-id-type="pmid">16276413</pub-id>
</element-citation>
</ref>
<ref id="B35-brainsci-08-00142">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Landers</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Bingley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Thomas-McArthur</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gleadall</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Cunliffe</surname>
<given-names>V.T.</given-names>
</name>
</person-group>
<article-title>The microtubule-severing protein spastin is essential for axon outgrowth in the zebrafish embryo</article-title>
<source/>Hum. Mol. Genet.
          <year>2006</year>
<volume>15</volume>
<fpage>2763</fpage>
<lpage>2771</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddl212</pub-id>
<pub-id pub-id-type="pmid">16893913</pub-id>
</element-citation>
</ref>
<ref id="B36-brainsci-08-00142">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trotta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Orso</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rossetto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Daga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Broadie</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The hereditary spastic paraplegia gene, spastin, regulates microtubule stability to modulate synaptic structure and function</article-title>
<source/>Curr. Biol.
          <year>2004</year>
<volume>14</volume>
<fpage>1135</fpage>
<lpage>1147</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2004.06.058</pub-id>
<pub-id pub-id-type="pmid">15242610</pub-id>
</element-citation>
</ref>
<ref id="B37-brainsci-08-00142">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munos</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Lessons from 60 years of pharmaceutical innovation</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2009</year>
<volume>8</volume>
<fpage>959</fpage>
<pub-id pub-id-type="doi">10.1038/nrd2961</pub-id>
<pub-id pub-id-type="pmid">19949401</pub-id>
</element-citation>
</ref>
<ref id="B38-brainsci-08-00142">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Concise review: Patient-derived olfactory stem cells: New models for brain diseases</article-title>
<source/>Stem Cells
          <year>2012</year>
<volume>30</volume>
<fpage>2361</fpage>
<lpage>2365</lpage>
<pub-id pub-id-type="doi">10.1002/stem.1220</pub-id>
<pub-id pub-id-type="pmid">22961669</pub-id>
</element-citation>
</ref>
<ref id="B39-brainsci-08-00142">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Patient-derived stem cells: Pathways to drug discovery for brain diseases</article-title>
<source/>Front. Cell. Neurosci.
          <year>2013</year>
<volume>7</volume>
<fpage>29</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00029</pub-id>
<pub-id pub-id-type="pmid">23543597</pub-id>
</element-citation>
</ref>
<ref id="B40-brainsci-08-00142">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matigian</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>McCurdy</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Féron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Filippich</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mowry</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fibroblast and lymphoblast gene expression profiles in schizophrenia: Are non-neural cells informative?</article-title>
<source/>PLoS ONE
          <year>2008</year>
<volume>3</volume>
<elocation-id>e2412</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0002412</pub-id>
<pub-id pub-id-type="pmid">18545665</pub-id>
</element-citation>
</ref>
<ref id="B41-brainsci-08-00142">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohnuki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Narita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ichisaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tomoda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<fpage>861</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id>
<pub-id pub-id-type="pmid">18035408</pub-id>
</element-citation>
</ref>
<ref id="B42-brainsci-08-00142">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soldner</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hockemeyer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Beard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Hargus</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Blak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mitalipova</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors</article-title>
<source/>Cell
          <year>2009</year>
<volume>136</volume>
<fpage>964</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.02.013</pub-id>
<pub-id pub-id-type="pmid">19269371</pub-id>
</element-citation>
</ref>
<ref id="B43-brainsci-08-00142">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimos</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Rodolfa</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Niakan</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Weisenthal</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Mitsumoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Croft</surname>
<given-names>G.F.</given-names>
</name>
<name>
<surname>Saphier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Leibel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goland</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons</article-title>
<source/>Science
          <year>2008</year>
<volume>321</volume>
<fpage>1218</fpage>
<lpage>1221</lpage>
<pub-id pub-id-type="doi">10.1126/science.1158799</pub-id>
<pub-id pub-id-type="pmid">18669821</pub-id>
</element-citation>
</ref>
<ref id="B44-brainsci-08-00142">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebert</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>F.F.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Mattis</surname>
<given-names>V.B.</given-names>
</name>
<name>
<surname>Lorson</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Svendsen</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Induced pluripotent stem cells from a spinal muscular atrophy patient</article-title>
<source/>Nature
          <year>2008</year>
<volume>457</volume>
<fpage>277</fpage>
<pub-id pub-id-type="doi">10.1038/nature07677</pub-id>
<pub-id pub-id-type="pmid">19098894</pub-id>
</element-citation>
</ref>
<ref id="B45-brainsci-08-00142">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Akamatsu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nihei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshizaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Modeling familial alzheimer’s disease with induced pluripotent stem cells</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>4530</fpage>
<lpage>4539</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr394</pub-id>
<pub-id pub-id-type="pmid">21900357</pub-id>
</element-citation>
</ref>
<ref id="B46-brainsci-08-00142">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avior</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sagi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Benvenisty</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Pluripotent stem cells in disease modelling and drug discovery</article-title>
<source/>Nat. Rev. Mol. Cell. Biol.
          <year>2016</year>
<volume>17</volume>
<fpage>170</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1038/nrm.2015.27</pub-id>
<pub-id pub-id-type="pmid">26818440</pub-id>
</element-citation>
</ref>
<ref id="B47-brainsci-08-00142">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>H.P.C.</given-names>
</name>
<name>
<surname>Livesey</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses</article-title>
<source/>Nat. Neurosci.
          <year>2012</year>
<volume>15</volume>
<pub-id pub-id-type="doi">10.1038/nn.3041</pub-id>
<pub-id pub-id-type="pmid">22306606</pub-id>
</element-citation>
</ref>
<ref id="B48-brainsci-08-00142">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Technical challenges in using human induced pluripotent stem cells to model disease</article-title>
<source/>Cell Stem Cell
          <year>2009</year>
<volume>5</volume>
<fpage>584</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2009.11.009</pub-id>
<pub-id pub-id-type="pmid">19951687</pub-id>
</element-citation>
</ref>
<ref id="B49-brainsci-08-00142">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Antosiewicz-Bourget</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Canto</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Giorgetti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Israel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kiskinis</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Somatic coding mutations in human induced pluripotent stem cells</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>63</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1038/nature09805</pub-id>
<pub-id pub-id-type="pmid">21368825</pub-id>
</element-citation>
</ref>
<ref id="B50-brainsci-08-00142">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bouckenheimer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Concise review: Assessing the genome integrity of human induced pluripotent stem cells: What quality control metrics?</article-title>
<source/>Stem Cells
          <year>2018</year>
<volume>36</volume>
<fpage>814</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1002/stem.2797</pub-id>
<pub-id pub-id-type="pmid">29441649</pub-id>
</element-citation>
</ref>
<ref id="B51-brainsci-08-00142">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turinetto</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Orlando</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Giachino</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Induced pluripotent stem cells: Advances in the quest for genetic stability during reprogramming process</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>1952</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18091952</pub-id>
<pub-id pub-id-type="pmid">28902128</pub-id>
</element-citation>
</ref>
<ref id="B52-brainsci-08-00142">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>B.-Y.</given-names>
</name>
<name>
<surname>Weick</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.-X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-Q.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.-C.</given-names>
</name>
</person-group>
<article-title>Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2010</year>
<volume>107</volume>
<fpage>4335</fpage>
<lpage>4340</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0910012107</pub-id>
<pub-id pub-id-type="pmid">20160098</pub-id>
</element-citation>
</ref>
<ref id="B53-brainsci-08-00142">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borgmann-Winter</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Willard</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mirza</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Turetsky</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>C.G.</given-names>
</name>
</person-group>
<article-title>Translational potential of olfactory mucosa for the study of neuropsychiatric illness</article-title>
<source/>Transl. Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e527</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2014.141</pub-id>
<pub-id pub-id-type="pmid">25781226</pub-id>
</element-citation>
</ref>
<ref id="B54-brainsci-08-00142">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Féron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>New techniques for biopsy and culture of human olfactory epithelial neurons</article-title>
<source/>Arch. Otolaryngol.–Head Neck Surg.
          <year>1998</year>
<volume>124</volume>
<fpage>861</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1001/archotol.124.8.861</pub-id>
<pub-id pub-id-type="pmid">9708710</pub-id>
</element-citation>
</ref>
<ref id="B55-brainsci-08-00142">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murrell</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Féron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wetzig</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cameron</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Splatt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bellette</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bianco</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Multipotent stem cells from adult olfactory mucosa</article-title>
<source/>Dev. Dyn.
          <year>2005</year>
<volume>233</volume>
<fpage>496</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1002/dvdy.20360</pub-id>
<pub-id pub-id-type="pmid">15782416</pub-id>
</element-citation>
</ref>
<ref id="B56-brainsci-08-00142">
<label>56.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Féron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Isolation of adult stem cells from the human olfactory mucosa</article-title>
<source/>Neural Progenitor Cells: Methods and Protocols
          <person-group person-group-type="editor">
<name>
<surname>Reynolds</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Deleyrolle</surname>
<given-names>P.L.</given-names>
</name>
</person-group>
<publisher-name>Humana Press</publisher-name>
<publisher-loc>Totowa, NJ, USA</publisher-loc>
<year>2013</year>
<fpage>107</fpage>
<lpage>114</lpage>
</element-citation>
</ref>
<ref id="B57-brainsci-08-00142">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matigian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Abrahamsen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Nouwens</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bellette</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beckhouse</surname>
<given-names>A.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disease-specific, neurosphere-derived cells as models for brain disorders</article-title>
<source/>Dis. Models Mech.
          <year>2010</year>
<volume>3</volume>
<fpage>785</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.005447</pub-id>
<pub-id pub-id-type="pmid">20699480</pub-id>
</element-citation>
</ref>
<ref id="B58-brainsci-08-00142">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bellette</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Crane</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Low dose tubulin-binding drugs rescue peroxisome trafficking deficit in patient-derived stem cells in hereditary spastic paraplegia</article-title>
<source/>Biol. Open
          <year>2014</year>
<volume>3</volume>
<fpage>494</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1242/bio.20147641</pub-id>
<pub-id pub-id-type="pmid">24857849</pub-id>
</element-citation>
</ref>
<ref id="B59-brainsci-08-00142">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.-S.</given-names>
</name>
<name>
<surname>Koentjoro</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Veivers</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Parkinson’s disease-associated human atp13a2 (park9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction</article-title>
<source/>Hum. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>2802</fpage>
<lpage>2815</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt623</pub-id>
<pub-id pub-id-type="pmid">24399444</pub-id>
</element-citation>
</ref>
<ref id="B60-brainsci-08-00142">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kozlov</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matigan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gatei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bellette</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wraith-Kijas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cochrane</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coulthard</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A patient-derived olfactory stem cell disease model for ataxia-telangiectasia</article-title>
<source/>Hum. Mol. Genet.
          <year>2013</year>
<volume>22</volume>
<fpage>2495</fpage>
<lpage>2509</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt101</pub-id>
<pub-id pub-id-type="pmid">23474819</pub-id>
</element-citation>
</ref>
<ref id="B61-brainsci-08-00142">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrahamsen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Matigian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bellette</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Raju</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Veivers</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A patient-derived stem cell model of hereditary spastic paraplegia with spast mutations</article-title>
<source/>Dis. Models Mech.
          <year>2013</year>
<volume>6</volume>
<fpage>489</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.010884</pub-id>
<pub-id pub-id-type="pmid">23264559</pub-id>
</element-citation>
</ref>
<ref id="B62-brainsci-08-00142">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tello Velasquez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Crane</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Mechanism of impaired microtubule-dependent peroxisome trafficking and oxidative stress in spast-mutated cells from patients with hereditary spastic paraplegia</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>27004</fpage>
<pub-id pub-id-type="doi">10.1038/srep27004</pub-id>
<pub-id pub-id-type="pmid">27229699</pub-id>
</element-citation>
</ref>
<ref id="B63-brainsci-08-00142">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Lepleux</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Makhlouf</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fregeac</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siquier-Pernet</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Philippe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gepner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rougeulle</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Profiling olfactory stem cells from living patients identifies miRNAs relevant for autism pathophysiology</article-title>
<source/>Mol. Autism
          <year>2016</year>
<volume>7</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-015-0064-6</pub-id>
<pub-id pub-id-type="pmid">26753090</pub-id>
</element-citation>
</ref>
<ref id="B64-brainsci-08-00142">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boone</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Loriod</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bergon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sbai</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Formisano-Tréziny</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gabert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Féron</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Axelrod</surname>
<given-names>F.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Olfactory stem cells, a new cellular model for studying molecular mechanisms underlying familial dysautonomia</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e15590</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0015590</pub-id>
<pub-id pub-id-type="pmid">21187979</pub-id>
</element-citation>
</ref>
<ref id="B65-brainsci-08-00142">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guzik</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Microtubule-dependent transport in neurons: Steps towards an understanding of regulation, function and dysfunction</article-title>
<source/>Curr. Opin. Cell Biol.
          <year>2004</year>
<volume>16</volume>
<fpage>443</fpage>
<lpage>450</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceb.2004.06.002</pub-id>
<pub-id pub-id-type="pmid">15261678</pub-id>
</element-citation>
</ref>
<ref id="B66-brainsci-08-00142">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiemer</surname>
<given-names>E.A.C.</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Deerinck</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Ellisman</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Subramani</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Visualization of the peroxisomal compartment in living mammalian cells: Dynamic behavior and association with microtubules</article-title>
<source/>J. Cell Biol.
          <year>1997</year>
<volume>136</volume>
<fpage>71</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.136.1.71</pub-id>
<pub-id pub-id-type="pmid">9008704</pub-id>
</element-citation>
</ref>
<ref id="B67-brainsci-08-00142">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antonenkov</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grunau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ohlmeier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hiltunen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Peroxisomes are oxidative organelles</article-title>
<source/>Antioxid. Redox Signal.
          <year>2010</year>
<volume>13</volume>
<fpage>525</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2009.2996</pub-id>
<pub-id pub-id-type="pmid">19958170</pub-id>
</element-citation>
</ref>
<ref id="B68-brainsci-08-00142">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrader</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Mitochondria and peroxisomes: Are the ‘big brother’ and the ‘little sister’ closer than assumed?</article-title>
<source/>Bioessays
          <year>2007</year>
<volume>29</volume>
<fpage>1105</fpage>
<lpage>1114</lpage>
<pub-id pub-id-type="doi">10.1002/bies.20659</pub-id>
<pub-id pub-id-type="pmid">17935214</pub-id>
</element-citation>
</ref>
<ref id="B69-brainsci-08-00142">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Giovanni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Clarkson</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Angelini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pegoraro</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Large-scale disruption of microtubule pathways in morphologically normal human spastin muscle</article-title>
<source/>Neurology
          <year>2004</year>
<volume>62</volume>
<fpage>1097</fpage>
<lpage>1104</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000118204.90814.5A</pub-id>
<pub-id pub-id-type="pmid">15079007</pub-id>
</element-citation>
</ref>
<ref id="B70-brainsci-08-00142">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denis</surname>
<given-names>I.C.</given-names>
</name>
</person-group>
<article-title>Revisiting the neuropathogenesis of zellweger syndrome</article-title>
<source/>Neurochem. Int.
          <year>2014</year>
<volume>69</volume>
<fpage>18</fpage>
</element-citation>
</ref>
<ref id="B71-brainsci-08-00142">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barry</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>O’Keeffe</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Peroxisomes: The neuropathological consequences of peroxisomal dysfunction in the developing brain</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <year>2013</year>
<volume>45</volume>
<fpage>2012</fpage>
<lpage>2015</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2013.06.019</pub-id>
<pub-id pub-id-type="pmid">23830890</pub-id>
</element-citation>
</ref>
<ref id="B72-brainsci-08-00142">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinberg</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Dodt</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Braverman</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>H.W.</given-names>
</name>
</person-group>
<article-title>Peroxisome biogenesis disorders</article-title>
<source/>Biochim. Biophys. Acta
          <year>2006</year>
<volume>1763</volume>
<fpage>1733</fpage>
<lpage>1748</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.09.010</pub-id>
<pub-id pub-id-type="pmid">17055079</pub-id>
</element-citation>
</ref>
<ref id="B73-brainsci-08-00142">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorman</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>DiMauro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>McFarland</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Suomalainen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thorburn</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Zeviani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Mitochondrial diseases</article-title>
<source/>Nat. Rev. Dis. Prim.
          <year>2016</year>
<volume>2</volume>
<fpage>16080</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2016.80</pub-id>
<pub-id pub-id-type="pmid">27775730</pub-id>
</element-citation>
</ref>
<ref id="B74-brainsci-08-00142">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Wali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Mallawaarachchi</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Gayeskiy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Minoche</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vievers</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cowley</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expanding the spectrum of PEX16 mutations and novel insights into disease mechanisms</article-title>
<source/>Mol. Genet. Metab. Rep.
          <year>2018</year>
<volume>16</volume>
<fpage>46</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2018.07.003</pub-id>
<pub-id pub-id-type="pmid">30094183</pub-id>
</element-citation>
</ref>
<ref id="B75-brainsci-08-00142">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrader</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fahimi</surname>
<given-names>H.D.</given-names>
</name>
</person-group>
<article-title>Peroxisomes and oxidative stress</article-title>
<source/>Biochim. Biophys. Acta
          <year>2006</year>
<volume>1763</volume>
<fpage>1755</fpage>
<lpage>1766</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.09.006</pub-id>
<pub-id pub-id-type="pmid">17034877</pub-id>
</element-citation>
</ref>
<ref id="B76-brainsci-08-00142">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atorino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Silvestri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Koppen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cassina</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ballabio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marconi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Casari</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia</article-title>
<source/>J. Cell Biol.
          <year>2003</year>
<volume>163</volume>
<fpage>777</fpage>
<lpage>787</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200304112</pub-id>
<pub-id pub-id-type="pmid">14623864</pub-id>
</element-citation>
</ref>
<ref id="B77-brainsci-08-00142">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halliwell</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and neurodegeneration: Where are we now?</article-title>
<source/>J. Neurochem.
          <year>2006</year>
<volume>97</volume>
<fpage>1634</fpage>
<lpage>1658</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03907.x</pub-id>
<pub-id pub-id-type="pmid">16805774</pub-id>
</element-citation>
</ref>
<ref id="B78-brainsci-08-00142">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kevin</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Colin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Ashley</surname>
<given-names>I.B.</given-names>
</name>
</person-group>
<article-title>Neurodegenerative diseases and oxidative stress</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2004</year>
<volume>3</volume>
<fpage>205</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">15031734</pub-id>
</element-citation>
</ref>
<ref id="B79-brainsci-08-00142">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertsch</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Blasig</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Grune</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>4-hydroxynonenal impairs the permeability of an in vitro rat blood–brain barrier</article-title>
<source/>Neurosci. Lett.
          <year>2001</year>
<volume>314</volume>
<fpage>135</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(01)02299-6</pub-id>
<pub-id pub-id-type="pmid">11704302</pub-id>
</element-citation>
</ref>
<ref id="B80-brainsci-08-00142">
<label>80.</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Wali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Recasens</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.-S.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Enhanced axon degeneration in Hereditary Spastic Paraplegia patient-derived neurons is reversed by tubulin-binding drugs</article-title>
<comment>under review</comment>
</element-citation>
</ref>
<ref id="B81-brainsci-08-00142">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saxton</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Hollenbeck</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>The axonal transport of mitochondria</article-title>
<source/>J. Cell Sci.
          <year>2012</year>
<volume>125</volume>
<fpage>2095</fpage>
<lpage>2104</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.053850</pub-id>
<pub-id pub-id-type="pmid">22619228</pub-id>
</element-citation>
</ref>
<ref id="B82-brainsci-08-00142">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westermann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Post-translational modifications regulate microtubule function</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2003</year>
<volume>4</volume>
<fpage>938</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="doi">10.1038/nrm1260</pub-id>
<pub-id pub-id-type="pmid">14685172</pub-id>
</element-citation>
</ref>
<ref id="B83-brainsci-08-00142">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Makarenkova</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Edelman</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>Hdac6 regulates mitochondrial transport in hippocampal neurons</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e10848</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0010848</pub-id>
<pub-id pub-id-type="pmid">20520769</pub-id>
</element-citation>
</ref>
<ref id="B84-brainsci-08-00142">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Checchi</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Nettles</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>H.C.</given-names>
</name>
</person-group>
<article-title>Microtubule-interacting drugs for cancer treatment</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2003</year>
<volume>24</volume>
<fpage>361</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-6147(03)00161-5</pub-id>
<pub-id pub-id-type="pmid">12871669</pub-id>
</element-citation>
</ref>
<ref id="B85-brainsci-08-00142">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amos</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>What tubulin drugs tell us about microtubule structure and dynamics</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2011</year>
<volume>22</volume>
<fpage>916</fpage>
<lpage>926</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2011.09.014</pub-id>
<pub-id pub-id-type="pmid">22001382</pub-id>
</element-citation>
</ref>
<ref id="B86-brainsci-08-00142">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gigant</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ravelli</surname>
<given-names>R.B.G.</given-names>
</name>
<name>
<surname>Roussi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Steinmetz</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Curmi</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Sobel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Knossow</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Structural basis for the regulation of tubulin by vinblastine</article-title>
<source/>Nature
          <year>2005</year>
<volume>435</volume>
<fpage>519</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1038/nature03566</pub-id>
<pub-id pub-id-type="pmid">15917812</pub-id>
</element-citation>
</ref>
<ref id="B87-brainsci-08-00142">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aneja</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chandra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>H.C.</given-names>
</name>
</person-group>
<article-title>Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation</article-title>
<source/>Mol. Pharmacol.
          <year>2003</year>
<volume>63</volume>
<fpage>799</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.1124/mol.63.4.799</pub-id>
<pub-id pub-id-type="pmid">12644580</pub-id>
</element-citation>
</ref>
<ref id="B88-brainsci-08-00142">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fassier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tarrade</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peris</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Courageot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mailly</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dalard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Delga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roblot</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lefèvre</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Job</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice</article-title>
<source/>Dis. Models Mech.
          <year>2013</year>
<volume>6</volume>
<fpage>72</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.008946</pub-id>
<pub-id pub-id-type="pmid">22773755</pub-id>
</element-citation>
</ref>
<ref id="B89-brainsci-08-00142">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millecamps</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Julien</surname>
<given-names>J.-P.</given-names>
</name>
</person-group>
<article-title>Axonal transport deficits and neurodegenerative diseases</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2013</year>
<volume>14</volume>
<fpage>161</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3380</pub-id>
<pub-id pub-id-type="pmid">23361386</pub-id>
</element-citation>
</ref>
<ref id="B90-brainsci-08-00142">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chevalier-Larsen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Holzbaur</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Axonal transport and neurodegenerative disease</article-title>
<source/>Biochim. Biophys. Acta
          <year>2006</year>
<volume>1762</volume>
<fpage>1094</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2006.04.002</pub-id>
<pub-id pub-id-type="pmid">16730956</pub-id>
</element-citation>
</ref>
<ref id="B91-brainsci-08-00142">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Vos</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grierson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ackerley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Role of axonal transport in neurodegenerative diseases</article-title>
<source/>Ann. Rev. Neurosci.
          <year>2008</year>
<volume>31</volume>
<fpage>151</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.31.061307.090711</pub-id>
<pub-id pub-id-type="pmid">18558852</pub-id>
</element-citation>
</ref>
<ref id="B92-brainsci-08-00142">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordgren</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fransen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Peroxisomal metabolism and oxidative stress</article-title>
<source/>Biochimie
          <year>2013</year>
<volume>98</volume>
<fpage>56</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.biochi.2013.07.026</pub-id>
<pub-id pub-id-type="pmid">23933092</pub-id>
</element-citation>
</ref>
<ref id="B93-brainsci-08-00142">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fransen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nordgren</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Apanasets</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Role of peroxisomes in ros/rns-metabolism: Implications for human disease</article-title>
<source/>Biochim. Biophys. Acta
          <year>2012</year>
<volume>1822</volume>
<fpage>1363</fpage>
<lpage>1373</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2011.12.001</pub-id>
<pub-id pub-id-type="pmid">22178243</pub-id>
</element-citation>
</ref>
<ref id="B94-brainsci-08-00142">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Axiak-Bechtel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dank</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clarkson</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Selting</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosol</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Espinosa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Decedue</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines</article-title>
<source/>Investig. New Drugs
          <year>2013</year>
<volume>31</volume>
<fpage>1609</fpage>
<lpage>1615</lpage>
<pub-id pub-id-type="doi">10.1007/s10637-013-0006-0</pub-id>
<pub-id pub-id-type="pmid">24026433</pub-id>
</element-citation>
</ref>
<ref id="B95-brainsci-08-00142">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunden</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Potuzak</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Hogan</surname>
<given-names>A.-M.L.</given-names>
</name>
<name>
<surname>Iba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S.X.</given-names>
</name>
<name>
<surname>Ballatore</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epothilone d improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy</article-title>
<source/>J. Neurosci.
          <year>2010</year>
<volume>30</volume>
<fpage>13861</fpage>
<lpage>13866</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3059-10.2010</pub-id>
<pub-id pub-id-type="pmid">20943926</pub-id>
</element-citation>
</ref>
<ref id="B96-brainsci-08-00142">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aneja</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dhiman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Idnani</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Awasthi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chandra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent</article-title>
<source/>Cancer Chemother. Pharmacol.
          <year>2007</year>
<volume>60</volume>
<fpage>831</fpage>
<lpage>839</lpage>
<pub-id pub-id-type="doi">10.1007/s00280-007-0430-y</pub-id>
<pub-id pub-id-type="pmid">17285314</pub-id>
</element-citation>
</ref>
<ref id="B97-brainsci-08-00142">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altmann</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Wartmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>O’Reilly</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Epothilones and related structures—A new class of microtubule inhibitors with potent in vivo antitumor activity</article-title>
<source/>Biochim. Biophys. Acta
          <year>2000</year>
<volume>1470</volume>
<fpage>M79</fpage>
<lpage>M91</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-419X(00)00009-3</pub-id>
<pub-id pub-id-type="pmid">10799747</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="brainsci-08-00142-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Effect of <italic>SPAST</italic> mutation and its reversal by tubulin-binding drugs. Axonal transport of peroxisomes is reduced in <italic>SPAST</italic> hereditary spastic paraplegia (HSP) cells with reduced retrograde transport leading to accumulation at the periphery, distal oxidative stress and axon degeneration. By increasing acetylated α-tubulin, tubulin-binding drugs restore peroxisome transport and the adverse consequences of the <italic>SPAST</italic> mutation.</p>
</caption>
<graphic xlink:href="brainsci-08-00142-g001"></graphic>
</fig>
<table-wrap id="brainsci-08-00142-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-08-00142-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Published studies of disease-associated cell deficits in <italic>SPAST</italic> patient-derived stem cell models and amelioration by tubulin-binding drugs.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Source of Patient-Derived Cells</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cell Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Number of Cell Lines Used</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Patient Cell Findings</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Effects of Tubulin-Binding Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Skin fibroblast cells [<xref ref-type="bibr" rid="B30-brainsci-08-00142">30</xref>]</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">iPS-derived glutamatergic neurons</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">2 patients/2 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced spastin</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">-</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased p60 katanin</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced axon number, length and branching</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased axonal swellings</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced mitochondria retrograde transport</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Skin fibroblast cells [<xref ref-type="bibr" rid="B29-brainsci-08-00142">29</xref>]</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">iPS-derived glutamatergic neurons</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">1 patient/1 control</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced spastin</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Vinblastine reduced axonal swellings</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased stabilised microtubules</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased axonal swellings</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced mitochondria retrograde transport</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">Olfactory mucosa cells [<xref ref-type="bibr" rid="B61-brainsci-08-00142">61</xref>]</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">ONS</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">9 patients/10 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">57% genes dysregulated</td>
<td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">Taxol and vinblastine restored stabilised microtubules and cell size</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced spastin</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced stabilised microtubules</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered mitochondria and peroxisome distribution</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced peroxisome transport speed</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced cell size</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Olfactory mucosa cells [<xref ref-type="bibr" rid="B58-brainsci-08-00142">58</xref>]</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">ONS</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">9 patients/8 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced stabilised microtubules</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Taxol, vinblastine, noscapine and epothilone D restored stabilised microtubules and rescued peroxisome transport</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced peroxisome transport speed</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Olfactory mucosa cells [<xref ref-type="bibr" rid="B62-brainsci-08-00142">62</xref>]</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">ONS and ONS-derived neuron-like cells</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">5 patients/5 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered peroxisome distribution</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">Epothilone D rescued increased vulnerability to oxidative stress</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced microtubule-dependent peroxisome transport</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced retrograde peroxisome transport</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased oxidative stress</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased vulnerability to induced oxidative stress</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Abbreviations: iPS cells: induced Pluripotent Stem cells; ONS: Olfactory Neurosphere-derived Stem cells.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>